Jon Napitupulu

Silence Therapeutics recently unveiled end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, an siRNA therapy, in individuals...

Innate Pharma announced preclinical data demonstrating the potential of IPH6501, its proprietary NK cell engager, for B-cell non-Hodgkin lymphoma...

Boston Pharmaceuticals announced positive Phase 2 study results for efimosfermin alfa, a long-acting FGF21 analogue, in patients with stage...

Vir Biotechnology announced positive end-of-treatment results from Part B of its MARCH Phase 2 clinical study. This study is...

Bristol Myers Squibb (BMS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...

Gilead Sciences recently released promising interim data from the Phase 3 ASSURE study on Livdelzi (seladelpar) for primary biliary...

Zura Bio, a clinical-stage immunology company, has submitted a Phase 2 study protocol to the FDA for tibulizumab. This...

Lineage Cell Therapeutics announced its third quarter 2024 financial and operating results, highlighting progress in its allogeneic cell therapy...

Perspectum, a medical imaging technology company, has received a substantial research grant from the U.S. Food and Drug Administration...

A coalition of prominent cancer organizations, alongside Illinois lawmakers, is advocating for the Illinois Cancer Patients Bill of Rights....